Navigation Links
NicOx Announces Departure of Damian Marron for CEO Position
Date:5/27/2008

e-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on NicOx S.A.'s website (http://www.nicox.com).


'/>"/>
SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
2. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
3. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
4. NicOx Opens U.S. Headquarters in New Jersey
5. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
6. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
7. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
10. Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System
11. Amarin Announces Completion of the First Tranche of $60 Million Private Placement

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...0 Cell Therapeutics, Inc...t the Ninth Circuit Court of Appeals reversed a U....be allowed to pursue all of its claims against The... Court for trial. CTI filed a complaint against T...ent consultant for CTI,s product TRISENOX, in 2007...
(Date:11/19/2009)... Danish Prince Joachim inaugurated ...nt in Kalundborg, Denmark, on Wednesday, November ...argest 2nd generation ethanol demonstration bioref...n the plant,s innovative process for converting st...the first to market with commercial enzymes for co...
(Date:11/19/2009)...PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex:...owing letter to its shareholders, discussing the C...a Biopharmaceuticals Holdings, Inc. (CHBP), an int...ople,s Republic of China. The merger gives NeoStem...eutical Co. Ltd., CHBP,s primary operating subsidi...
(Date:11/19/2009)...PRNewswire/ - Aegera Therapeutics Inc. announced t...ed Phase 2B study of AEG35156, a targeted antisens...e oncology indications. ,, The study, entitled ...inked Inhibitor of Apoptosis (XIAP) Antisense AEG3...e and Idarubicin in AML Following Failure of a Sin...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...nostic Systems, Inc., (OTC Bulletin Board: IMDS) a...stems, announced today that its distributor,The Oy...r Mammography,System (CTLM(R)) for Jerusalem, Isra...20040412/IMDSLOGO ), The Oyamo group obtained th...h which permitted the shipment and initiated the p...
...ectious Disease Research, Institute and Eli Lilly ... SEATTLE, Oct. 7 The Lilly TB Drug Discovery,Ini...ompounds for further,development into tuberculosis...h Summit plc (LSE: SUMM) of Oxfordshire, UK, and t...of Tokyo for two compounds that have shown,potenti...
...nc.,(OTC Bulletin Board: ABOS) today announced tha...ioartificial liver system, HepatAssist, to HepaLif... Boston-based biotechnology,company developing pro...e,protect and save lives, addressing prevalent hum...ed $450,000 in cash and a five year warrant,to pur...
Other Biology Technology:Imaging Diagnostic Systems Receives its First Order for its CT Laser Mammography System for Israel 2The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 2The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 3The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 4The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 5Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc. 2Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc. 3
(Date:11/23/2009)... Calif. - By producing some of the highest resolut...es, scientists have a deeper understanding how bio...earch may lead to a new treatment for kidney stone...ars in the Nov. 23 online edition of the journal ...explores how peptides interact with mineral surfac...
(Date:11/23/2009)... Ill. Two new studies reveal in unprecedented det...s to assemble new proteins and guide them toward t...used molecular dynamics flexible fitting (MDFF) to...prominent molecular partners. , The first study...ces , concerns the intimate signaling between the ...
(Date:11/23/2009)... , , , , , , , ... , AUDIO: , Dr Andrew Marshall, from t...k, discusses the discovery of Kinyongia magombera... Click here for more information. , , ... , , , , , , , , , ...
Breaking Biology News(10 mins):Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Datafarm Responds to Health Canada 26apos 3Bs Announcement of Hybrid eCTD Submission Procedural Simplification 14762 1Datafarm Responds to Health Canada 26apos 3Bs Announcement of Hybrid eCTD Submission Procedural Simplification 14762 2Radiation Therapy Options for Mesothelioma Patients Sponsored by MesoCare org 60947 1The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim com 60944 1The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim com 60944 2The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim com 60944 3The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim com 60944 4The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim com 60944 5
...er a plant withers unproductively or thrives in sa...logists. , The cellular mechanism that controls s...ant by a Texas AgriLife Research scientist collabo...lycan, a carbohydrate linked to a protein in plant...function for plant growth and to cause certain all...
...Universitys Scott A. Strobel, Professor of Molecul...he prestigious Schering-Plough Research Institute ...f Biochemistry and Molecular Biology to recognize ... researchers early in their careers. , Strobel wi...NA Catalysis: Ribozymes, Ribosomes, and Riboswitch...
...RLEANS, April 7, 2008 The Global Innovation Imper... experts gathering for their first session at the ...eting in New Orleans. Gii, a joint collaboration b... and the Society of Chemical Industry, seeks to co...issues by developing science-based solutions, part...
Other Biology News:Salt-tolerant gene found in simple plant nothing to sneeze at 2Yale University's Strobel recognized for work on RNA 2At ACS' national meeting, global initiative set to tackle water issues 2
1/4" to 1/8" Adapter for Reflectance Probe Holder from Ocean Optics
SHEEP SERUM (WITH 0.09% AZIDE) from AbD Serotec
...acity to self renew and their ability to different...hich can commit to further maturation along specif...of differentiating into multiple cell types includ...ng the isolation and expansion of NSCs, the status...
Mouse Anti-Macrophage L1 protein Calprotectin Monoclonal Antibody, Unconjugated, Clone B314.1 (MAC 387) from Abcam
Biology Products: